MenB Immunization Fails to Shield Men Against Gonorrhoea, Research Indicates
Major Clinical Trial Reveals Vaccine Ineffectiveness
MenB vaccine offers men no protection – A comprehensive new investigation reveals that the Meningitis B immunization provides no meaningful defense against gonorrhoea transmission, even though it has been made available to vulnerable male populations. Health experts in the United Kingdom initiated the vaccination rollout for men who engage in sexual relationships with other men during the previous year, following earlier research that hinted at potential protective benefits. Nevertheless, an extensive Australian trial, detailed in the New England Journal of Medicine, uncovered no statistically meaningful variation in gonorrhoea rates between vaccinated individuals and those receiving a placebo. The UK Health Security Agency has stated that additional domestic investigations will yield “more robust data” and currently advises against any swift modifications to the current program. Gonorrhoea represents a frequently occurring bacterial illness spread primarily through intimate contact. While it commonly produces discomfort, abnormal secretions, and genital swelling, certain infected individuals experience no noticeable symptoms whatsoever. The immunization, formally designated as the 4CMenB vaccine, was originally developed to shield infants from meningitis B. The microorganisms responsible for both conditions share close biological relationships, which initially sparked optimism about cross-protection. Beginning in August 2025, gay and bisexual men participating in same-sex relationships gained access to the MenB vaccine throughout the UK following multiple investigations that documented a thirty-eight percent decline in gonorrhoea cases among vaccinated recipients.
GoGoVax Trial Demonstrates Lack of Protection
Despite earlier encouraging results, fresh research conducted by the University of New South Wales in Sydney presents compelling evidence challenging the vaccine’s effectiveness. The GoGoVax clinical trial followed 587 male participants across a two-year observation period. Researchers divided the cohort equally, administering the MenB vaccine to one group while the other received an inactive placebo. The outcomes revealed nearly identical infection rates between both populations: 291 new gonorrhoea cases emerged among vaccinated men, compared to 285 infections in the placebo group. According to the publication’s authors, these results align with two additional independent investigations, collectively offering “strong evidence that the MenB vaccine is not effective for gonorrhea prevention.”
Dr Mary Ramsay, director of public health programmes at UKHSA UK, emphasized that it was “important to consider a range of evidence”. She noted that “Over 30,000 people in England have started this course of vaccination, and this will provide more robust data on vaccine impact and effectiveness. These findings will be published in due course.”
The agency confirmed it is maintaining its current stance without implementing alterations at this juncture. Meanwhile, gonorrhoea incidence continues reaching unprecedented levels when measured against a decade of historical data. England experienced its highest recorded figure of 82,592 cases during 2022. Although subsequent figures declined to 63,943 by 2025, these numbers remain twice as high as the 2015 baseline.
Health Officials Respond to Findings
According to the European Centre for Disease Prevention and Control, men who have sex with men constitute the most heavily impacted demographic. Dr Odile Harrison, associate professor at the University of Oxford’s Population Health Infectious Disease Epidemiology Unit, characterized the outcomes as “disappointing” yet cautioned against viewing them as conclusive.
“Gonorrhoea remains a major global public health threat, particularly with the continued emergence of antimicrobial resistance, and an effective vaccine remains a high priority,” she stated.
Taku Mukiwa, head of health programmes at the sexual health charity Terrence Higgins Trust, echoed concerns about the results and urged the Joint Committee on Vaccination and Immunisation to reevaluate the vaccination initiative.
“If the evidence has changed, the approach has to change too.” He continued, “Rates of gonorrhoea in the UK are sky high and this is particularly true among gay and bisexual men, and we’re seeing more antibiotic resistant strains of the infection.”
Mukiwa concluded by emphasizing established prevention strategies: “What we do know for sure is that condoms and regular testing remain the cornerstones for preventing and stopping onward transmission of STIs, and we must continue to work to bring down the stubbornly high rates of STIs in this country.” The ongoing debate highlights the complexity of vaccine development and the necessity for comprehensive, long-term monitoring as public health officials navigate rising infection rates and evolving treatment challenges.
